Strategic Advisory
We offer big firm capabilities with a small firm feel, providing best-in-class expertise with high touch service.
Our team of leading professionals delivers innovative solutions to highly complex challenges across M&A, Strategic Advisory and Capital Raising.
What We Do
Advise corporate boards and management teams on strategic acquisitions, divestitures, and combinations
What We Do
Team members have collectively advised on $3+ trillion in transactions
What We Do
Provide industry-leading capabilities in capital structure advisory
What We Do
Deliver significant cross-border experience and capabilities
What We Do
Provide customized M&A and corporate finance solutions with dedicated Structured Products team
What We Do
Lead capital raises for early, mid, and late stage enterprises
Services
M&A
- Mergers & acquisitions
- Joint ventures
- Divestitures
- Takeover defenses
- Spin-offs
- Asset swaps
Capital Markets Advisory
- Capital structure
- Acquisition finance
- Debt execution
- SPACs
- Pre-IPO and IPO
- Private capital raising
- Structured products
Select Transactions
$63 billion

on its acquisition of

$59 billion

on its merger with

$48 billion

on the cash offer from

$35 billion

on its merger with

$26 billion

on its acquisition by

$25.3 billion

Strategic Capital Markets Advisor on multiple debt and equity transactions
$21.4 billion

on the sale of its
BioPharma business to

£14.3 billion

on its all share combination with

$17 billion

on its combination with

$12.3 billion

on its acquisition of

$10.5 billion

on its merger with

$10 billion

on its separation into two independent publicly traded companies
€10.1 billion

on the IPO and €10.1bn stake purchase in

$9.0 billion

on its business combination with

$8.0 billion

on its sale to

$7.3 billion 1

on its acquisition of

$7 billion

on its sale to

$5.1 billion

on its acquisition of

$4.8 billion

on the sale of 25% in Repsol Upstream to

£3.4 billion
Financial adviser to

on its recommended offer from

$4.25 billion

on the sale of Bellagio Real Estate to

$4.0 billion

on the sale of TCOLV’s real property assets to a partnership among

$3.9 billion

on its acquisition of

$3.8 billion

on its acquisition of

$3.6 billion

on its acquisition of

$2.7 billion

(owned by KKR and KSL) on its sale to

€1.9 billion

on its acquisition of

$1.6 billion

on the sale of TCOLV’s casino and hotel operations to

$63 billion

on its acquisition of

$59 billion

on its merger with

$48 billion

on the cash offer from

$35 billion

on its merger with

$26 billion

on its acquisition by

$25.3 billion

Strategic Capital Markets Advisor on multiple debt and equity transactions
$21.4 billion

on the sale of its
BioPharma business to

£14.3 billion

on its all share combination with

$17 billion

on its combination with

$12.3 billion

on its acquisition of

$10.5 billion

on its merger with

$10 billion

on its separation into two independent publicly traded companies
€10.1 billion

on the IPO and €10.1bn stake purchase in

$9.0 billion

on its business combination with

$8.0 billion

on its sale to

$7.3 billion 1

on its acquisition of

$7 billion

on its sale to

$5.1 billion

on its acquisition of

$4.8 billion

on the sale of 25% in Repsol Upstream to

£3.4 billion
Financial adviser to

on its recommended offer from

$4.25 billion

on the sale of Bellagio Real Estate to

$4.0 billion

on the sale of TCOLV’s real property assets to a partnership among

$3.9 billion

on its acquisition of

$3.8 billion

on its acquisition of

$3.6 billion

on its acquisition of

$2.7 billion

(owned by KKR and KSL) on its sale to

€1.9 billion

on its acquisition of

$1.6 billion

on the sale of TCOLV’s casino and hotel operations to

1. | Pending. |
---|
Leadership
A highly skilled group of veteran practitioners with diverse experience across industries, disciplines and geographies.